These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34122062)

  • 1. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road.
    Beltagy A; Aghamajidi A; Trespidi L; Ossola W; Meroni PL
    Front Pharmacol; 2021; 12():621247. PubMed ID: 34122062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation.
    Levy RA; de Jesús GR; de Jesús NR; Klumb EM
    Autoimmun Rev; 2016 Oct; 15(10):955-63. PubMed ID: 27490204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis.
    Lee A; Scott LJ
    BioDrugs; 2020 Apr; 34(2):235-244. PubMed ID: 32207094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pre- and post-authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation.
    Ghalandari N; Dolhain RJEM; Hazes JMW; Siezen CLE; van der Laan JW; Crijns HJMJ; van Puijenbroek EP; van der Woude CJ
    Br J Clin Pharmacol; 2020 Mar; 86(3):580-590. PubMed ID: 31633830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.
    Porter C; Armstrong-Fisher S; Kopotsha T; Smith B; Baker T; Kevorkian L; Nesbitt A
    J Reprod Immunol; 2016 Aug; 116():7-12. PubMed ID: 27123565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
    Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.
    Gisbert JP; Chaparro M
    Drugs; 2020 Jul; 80(11):1085-1100. PubMed ID: 32562207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications in pregnancy and breastfeeding.
    Tosounidou S; Gordon C
    Best Pract Res Clin Obstet Gynaecol; 2020 Apr; 64():68-76. PubMed ID: 32019728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment with immunosuppressive and biologic drugs of pregnant women with systemic rheumatic or autoimmune disease].
    Alijotas-Reig J; Esteve-Valverde E; Ferrer-Oliveras R
    Med Clin (Barc); 2016 Oct; 147(8):352-360. PubMed ID: 27389618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptions of Pregnancy and Lactation from the Pregnancy and Lactation Autoimmune Network Registry.
    Mills BS; Dao KH; Tecson KM; Beil EF; Tate R; Cush JJ
    J Rheumatol; 2020 Jan; 47(1):149-154. PubMed ID: 30936282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic rheumatic diseases: From biological agents to small molecules.
    Sarzi-Puttini P; Ceribelli A; Marotto D; Batticciotto A; Atzeni F
    Autoimmun Rev; 2019 Jun; 18(6):583-592. PubMed ID: 30959214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
    Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
    Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers.
    Shimada H; Kameda T; Kanenishi K; Miyatake N; Nakashima S; Wakiya R; Kato M; Miyagi T; Mansour MMF; Hata T; Kadowaki N; Dobashi H
    Clin Rheumatol; 2019 May; 38(5):1453-1458. PubMed ID: 30729372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients.
    Förger F; Zbinden A; Villiger PM
    Joint Bone Spine; 2016 May; 83(3):341-3. PubMed ID: 26617214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of biologics in pregnant patients with rheumatic disease.
    Østensen M
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):661-669. PubMed ID: 28326845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
    Roseira J; Ramos J
    Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.